Volketswil, April 19, 2011 – Since the launch of Hocoma’s first gait therapy device in 2001, the LokomatPro has established itself as an effective intervention for improving over-ground walking function in patients who suffer of neurological diseases and injuries resulting in gait impairment. In strong collaboration with clinical research partners, Hocoma has now developed a new and more compact version of the LokomatPro. The new version of the LokomatPro has been developed with the needs of patients and clinics in mind and provides extensive locomotion therapy to help patients trigger great improvements. It features a new and more compact design and is equipped with the Augmented Feedback and a touch screen as a standard. In the future, upgrading options (e.g. additional degrees of freedom at the hip joint, sophisticated control strategy, higher gait speed) will extend the LokomatPro as a sophisticated gait training device supporting the therapists and the patients in reaching their therapy goals. As the preceding versions, with the optional Pediatric Orthoses, the LokomatPro provides intensive locomotion therapy also for the treatment of children with cerebral palsy or other neurological disorders.
Over 300 Lokomat in over 50 countries worldwide
The Lokomat, a driven gait orthosis, is used for robotic gait training of neurological patients with movement disorders caused by stroke, spinal cord injury, traumatic brain injury, multiple sclerosis, Parkinson’s disease or other neurological diseases and injuries. The Lokomat has been available on the market since 2001 and has been a crucial improvement in the art and science of locomotion therapy. Currently, there are over 300 Lokomat systems successfully applied in over 50 countries worldwide. With operating hours of 270,000 and an estimated average of 6 hours per patient approximately 45,000 patients have been trained so far.